




KIZO  **O**
TECHNOLOGY VENTURES

The logo for KIZO Technology Ventures features the word "KIZO" in a bold, black, sans-serif font. The letter "O" is replaced by a stylized globe icon composed of horizontal, curved lines in shades of green and yellow. Below "KIZO" is the text "TECHNOLOGY VENTURES" in a smaller, grey, sans-serif font. The background is white with three large, light grey, curved shapes that resemble stylized waves or abstract forms.

OUR PILLARS

KIZOO TECHNOLOGY CAPITAL
(Venture Investments)



REJUVENATION NOW

(Forever Healthy Foundation)

STARTUP SUMMIT

(annual conference)

Building a REJUVENATION NETWORK



KIZOO
TECHNOLOGY VENTURES

WE ARE KIZOO

- Entrepreneurs in high growth tech and biotech companies
- Venture Capital Investor since 2008
- Global scope, evergreen structure, early stage, lead and partner role
- Switch to life science / longevity biotech in 2016



A DEDICATED TEAM



Michael Greve



Frank Schueler



Patrick Burgermeister



REJUVENATION STARTUP SUMMIT

- Focus on translation of longevity biotech companies
- World's largest gathering of longevity startups
- Bringing together entrepreneurs, science, investors & media in Berlin with 400+ participants
- 40+ speakers (keynotes by Profs Verdin and Kennedy)
- <https://forever-healthy.org/summit/>



LONGEVITY BIOTECH STARTUPS

- Mission-driven investments in early stage companies that open completely new categories of treatment
- Mitochondria as novel treatment modality
- Enzymes breaking AGE crosslinks
- Reversal of atherosclerosis and calcified vessels
- Killing cancer independent of strain
- Rejuvenating the blood and immune system



CELLVIE



CYCLARITY
THERAPEUTICS



LIFT BioSciences
INNATELY CURING CANCER

Elastrin
Restoring the Elastic of Life




Elevian

turn.bio




KEY INVESTMENT CELLVIE

- Originated at the Boston Children's Hospital (group of prof James McCully), strong IP protection
- Mitochondria as a non-immunogenic, off-the-shelf, sub-cellular treatment modality
- Already applied in humans, potential in ischemia reperfusion, oncology, sarcopenia, transplantation
- Operational team at Technopark Zurich, Switzerland




KEY INVESTMENT REVEL

- Enzyme platform technology to break up AGEs (protein-sugar crosslinks) reversing toxic age-related changes
- Targeting multiple indications of aging , focus on inflammatory diseases of the eye, joints & cardiovascular
- Seed round over USD 8.4 mio announced in March 2022
- Based in the San Francisco, USA, and led by Aaron Cravens, CEO




KEY INVESTMENT CYCLARITY

- Damage-repair approach, truly disease-modifying
- Targeting soft plaques > a root cause of atherosclerosis, heart attacks and strokes
- Clearing oxidised cholesterol with a special form of cyclodextrins
- Into clinic in 2023 (UK Innovation passport programme)
- Led by founding CEO and VP Research of SRF




KEY INVESTMENT LIFT BIOSCIENCES

- Using the innate immune system to destroy solid tumours irrespective of origin or mutation
- The world's only alpha neutrophil based oncology therapy
- Strong tumoroid data, entry into clinic within 18 months
- Team led by Alex Blyth CEO and Oxana Polyakova CSO
- Based in London UK and Belgium (JLabs)




KEY INVESTMENT ELASTRIN

- Addressing a root cause of age-related tissue stiffening and loss of organ function
- Targeted nanoparticles to de-calcify damaged elastin fibres and blood vessels
- Team led by Matthias Breugelmans and prof Naren Vyavahare, based at Greenville, South Carolina
- Last financing round (\$ 10 mio) before entering clinical trials in 2023



KEY INVESTMENT MOGLING BIO

- Based on research by Hartmut (Ulm University, Germany) and Yi (CCHMC, Cincinnati, USA)
- Treating hematopoietic stem cells, thereby rejuvenating both, the blood and immune system
- Targeting multiple myeloma, myelodysplastic syndrome and boosting vaccination responses
- Led by industry veteran Jürgen Reess, CEO



WWW.KIZOO.COM

Frank Schueler, MD Kizoo Technology Capital, fs@kizoo.com

Matthias Hornberger, CFO Kizoo Technology Capital, mho@kizoo.com

Patrick Burgermeister, Partner Kizoo Technology Ventures, pb@kizoo.com

